115 related articles for article (PubMed ID: 21755708)
21. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
Mahmud A; Feely J
Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers.
Chen MH; Colan SD; Diller L
Circ Res; 2011 Mar; 108(5):619-28. PubMed ID: 21372293
[TBL] [Abstract][Full Text] [Related]
23. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines.
Germanakis I; Kalmanti M; Parthenakis F; Nikitovic D; Stiakaki E; Patrianakos A; Vardas PE
Int J Cardiol; 2006 Apr; 108(2):212-5. PubMed ID: 16290101
[TBL] [Abstract][Full Text] [Related]
24. Differential impact of metabolic syndrome on arterial stiffness and wave reflections: focus on distinct definitions.
Vyssoulis GP; Pietri PG; Karpanou EA; Vlachopoulos CV; Kyvelou SM; Spanos P; Cokkinos DV; Stefanadis CI
Int J Cardiol; 2010 Jan; 138(2):119-25. PubMed ID: 18804878
[TBL] [Abstract][Full Text] [Related]
25. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group.
Shankar SM; Marina N; Hudson MM; Hodgson DC; Adams MJ; Landier W; Bhatia S; Meeske K; Chen MH; Kinahan KE; Steinberger J; Rosenthal D;
Pediatrics; 2008 Feb; 121(2):e387-96. PubMed ID: 18187811
[TBL] [Abstract][Full Text] [Related]
26. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
[TBL] [Abstract][Full Text] [Related]
27. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H
Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
[TBL] [Abstract][Full Text] [Related]
28. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines.
Pudil R; Horacek JM; Strasova A; Jebavy L; Vojacek J
Exp Oncol; 2008 Jun; 30(2):160-2. PubMed ID: 18566583
[TBL] [Abstract][Full Text] [Related]
29. Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study.
Protogerou A; Blacher J; Stergiou GS; Achimastos A; Safar ME
J Am Coll Cardiol; 2009 Feb; 53(5):445-51. PubMed ID: 19179203
[TBL] [Abstract][Full Text] [Related]
30. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children.
Aggarwal S; Pettersen MD; Bhambhani K; Gurczynski J; Thomas R; L'Ecuyer T
Pediatr Blood Cancer; 2007 Nov; 49(6):812-6. PubMed ID: 17171687
[TBL] [Abstract][Full Text] [Related]
31. Predicting and preventing the cardiotoxicity of cancer therapy.
Anderson B; Sawyer DB
Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):1023-33. PubMed ID: 18666852
[TBL] [Abstract][Full Text] [Related]
32. Acute cardiac functional and morphological changes after Anthracycline infusions in children.
Ganame J; Claus P; Eyskens B; Uyttebroeck A; Renard M; D'hooge J; Gewillig M; Bijnens B; Sutherland GR; Mertens L
Am J Cardiol; 2007 Apr; 99(7):974-7. PubMed ID: 17398195
[TBL] [Abstract][Full Text] [Related]
33. Arterial Stiffness Use for Early Monitoring of Cardiovascular Adverse Events due to Anthracycline Chemotherapy in Breast Cancer Patients. A Pilot Study.
Souza CA; Simões R; Borges KBG; Oliveira AN; Zogeib JB; Alves B; Malachias MVB; Drummond-Lage AP; Rezende BA
Arq Bras Cardiol; 2018 Nov; 111(5):721-728. PubMed ID: 30281690
[TBL] [Abstract][Full Text] [Related]
34. The impact of arteriovenous fistulas on aortic stiffness in patients with chronic kidney disease.
Utescu MS; LeBoeuf A; Chbinou N; Desmeules S; Lebel M; Agharazii M
Nephrol Dial Transplant; 2009 Nov; 24(11):3441-6. PubMed ID: 19509025
[TBL] [Abstract][Full Text] [Related]
35. Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.
Silber JH; Cnaan A; Clark BJ; Paridon SM; Chin AJ; Rychik J; Hogarty AN; Cohen MI; Barber G; Rutkowsky M; Kimball TR; Delaat C; Steinherz LJ; Zhao H; Tartaglione MR
Am Heart J; 2001 Oct; 142(4):577-85. PubMed ID: 11579345
[TBL] [Abstract][Full Text] [Related]
36. Association between brachial-ankle pulse wave velocity and 3-year mortality in community-dwelling older adults.
Miyano I; Nishinaga M; Takata J; Shimizu Y; Okumiya K; Matsubayashi K; Ozawa T; Sugiura T; Yasuda N; Doi Y
Hypertens Res; 2010 Jul; 33(7):678-82. PubMed ID: 20431594
[TBL] [Abstract][Full Text] [Related]
37. Presence of prolonged dispersion of qt intervals in late survivors of childhood anthracycline therapy.
Gupta M; Thaler HT; Friedman D; Steinherz L
Pediatr Hematol Oncol; 2002 Dec; 19(8):533-42. PubMed ID: 12487828
[TBL] [Abstract][Full Text] [Related]
38. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors.
Hudson MM; Rai SN; Nunez C; Merchant TE; Marina NM; Zalamea N; Cox C; Phipps S; Pompeu R; Rosenthal D
J Clin Oncol; 2007 Aug; 25(24):3635-43. PubMed ID: 17704413
[TBL] [Abstract][Full Text] [Related]
39. Late cardiotoxic effects of anthracycline chemotherapy in childhood malignancies.
Roodpeyma S; Moussavi F; Kamali Z
J Pak Med Assoc; 2008 Dec; 58(12):683-7. PubMed ID: 19157322
[TBL] [Abstract][Full Text] [Related]
40. Cardiotoxicity: anthracyclines and long term cancer survivors.
Patanè S
Int J Cardiol; 2014 Oct; 176(3):1326-8. PubMed ID: 25129289
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
